Transgene Announces Share Trading Suspension
Transgene (Euronext Paris: TNG) has requested a trading suspension for its shares on Euronext Paris starting on the morning of November 26, pending the announcement of its capital increase results. This decision is made to ensure that all investors have access to the necessary information before trading resumes.
Expected Resumption of Trading
It is anticipated that trading will resume on November 27, allowing investors to re-engage with the market under updated circumstances. The process aims to provide clarity and maintain transparency for stakeholders.
Communication Channels for Investors
For additional information and answers to inquiries, investors can reach out via the following contacts:
Transgene:
Caroline Tosch, Corporate and Scientific Communications Manager
Contact: +33 (0)3 68 33 27 38
Email: communication@transgene.fr
Investors & Analysts:
Lucie Larguier, Chief Financial Officer (CFO)
Email: investorrelations@transgene.fr
Contact: +33 (0)3 88 27 91 00/03
About Transgene
Transgene is a pioneering biotechnology company focused on developing immunotherapy products for cancer treatment. The company's innovative portfolio features several viral vector-based immunotherapies currently undergoing clinical evaluation. TG4050 stands out as the lead candidate, utilizing the advanced myvac® platform tailored to deliver personalized treatments, and has shown promising results for patients with head and neck cancer.
Innovation and Technology
Transgene continually explores cutting-edge technologies designed to improve patient outcomes. Through its myvac® immunotherapy, the company delivers individualized treatments that leverage artificial intelligence to identify and select specific tumor mutations, integrating them into viral vectors.
Research and Development Focus
The company also explores other promising candidates, including BT-001, a cutting-edge oncolytic virus emerging from the invir.IO® platform. This platform underlines Transgene's commitment to innovation and exploration in their field, setting the stage for the development of next-generation therapies.
Frequently Asked Questions
What prompted the suspension of trading?
The suspension was requested to provide clarity and transparency for investors regarding the upcoming announcements related to the capital increase.
When will trading resume?
Trading is expected to resume on November 27, allowing investors to react to updated information.
Who can I contact for more information?
Investors can reach out to Caroline Tosch or Lucie Larguier through their provided contact information for inquiries.
What is Transgene's primary focus?
Transgene is dedicated to developing personalized immunotherapy products for cancer treatment, leveraging viral vector technology.
How can I stay updated on Transgene's developments?
Follow Transgene on their social media platforms for the latest news and updates about their research and advancements.